ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,756.00
-19.00 (-1.07%)
21 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -19.00 -1.07% 1,756.00 1,753.00 1,754.00 1,770.00 1,740.00 1,770.00 8,298,343 16:35:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.65 72.19B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,775p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,820.00p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £72.19 billion. Gsk has a price to earnings ratio (PE ratio) of 14.65.

Gsk Share Discussion Threads

Showing 13651 to 13675 of 33175 messages
Chat Pages: Latest  547  546  545  544  543  542  541  540  539  538  537  536  Older
DateSubjectAuthorDiscuss
24/1/2017
08:58
Defensive qualities, too cheap imho

Tks Essential

Bought a few BT.A on the 20% dip this morning, just to tuck away for the pension fund

ny boy
24/1/2017
08:44
A month to go 'til next ex. dividend (23 Feb). Amazing how quickly it comes around ..... ;0)
tradermichael
24/1/2017
08:15
The webcast from the recent JPM Pharma conference is on the investors site,
for anyone interested.

essentialinvestor
23/1/2017
20:50
Bouncy bouncy stateside ;-)
philanderer
23/1/2017
16:33
Agree, any new super-antibiotic would have be used sparingly and therefore would have to be sold at a high price. Not easy, let alone find one.
alphorn
23/1/2017
16:32
Trump has also made some worrying comments on US vaccination programmes.

He has appointed a well known vaccine sceptic to review this, a member of the Kennedy
family from memory.

essentialinvestor
23/1/2017
16:30
Part of the problem with developing new antibiotics is their commercial appeal. If we have an anitbiotic of last resort, you don't want to use it a lot to allow the bacteria to gain resistance..

Much needed though. Not sure where the market is heading. Trumps easy answers of lowering tax, spending more on infrastructure and imposing trade tarriffs doesn't sound like it is thought through. I am already concerned that this will be a presidency that runs on rhetoric not facts.

dr biotech
23/1/2017
16:24
Yes that is the case, however many antibiotic compounds are not on M/R.

It tends to be more common on antibiotics used to treat chronic conditions,
acne etc. Minocycline M/R as one example.

essentialinvestor
23/1/2017
16:08
There are other ways to extend IP protection - eg, delivery methods, combos, delayed release methods to name three.
alphorn
23/1/2017
16:04
Another small amount.


M, you cynic ).

essentialinvestor
23/1/2017
15:54
"I hoped there would be an agreement to extend patent duration in developed(not developing) markets to help spark extra commercial interest in research."

We wish. I don't think those in power have any intellect to see that far Essential.

minerve
23/1/2017
15:47
Yes valid observation.

I hoped there would be an agreement to extend patent duration in developed(not developing) markets to help spark extra commercial interest in research.

essentialinvestor
23/1/2017
15:41
FTSE100 now back where it ended 2016
philanderer
23/1/2017
14:36
Richard Sykes talked about the antibiotic problem around 20 years ago. He saw it coming and that is probably why GSK continued with its research.
alphorn
23/1/2017
14:30
Gary thanks. taking things a little easy for a few weeks to get my BP
down, will have a look though.


Read a case on antibiotic resistance over the weekend where 28 different antibiotics were tried and everyone failed, the patient died.

GSK one of the few major pharmas still engaged in antibiotic discovery/research,
for all our sakes we badly need breakthroughs in this area.

essentialinvestor
23/1/2017
14:25
EI,Have a look at CARD,near a 52 week low of 232,and yielding nearly 10% with the Special Dividend.
garycook
23/1/2017
14:18
Nicely done on PHTM, was very tempted at 1.43 but passed.

Under 1524 my next level, also depends on what else is available/interesting.

essentialinvestor
23/1/2017
14:13
Added a few more @ 1530p for the pension fund
ny boy
23/1/2017
13:28
Yes agree, if the UKX heads 5/6% it makes that more likely.
essentialinvestor
23/1/2017
13:19
EI,If the UKX falls further,then so will GSK,also with the USD dropping today,makes it worse.I hope I am wrong,but we will see in due course.
garycook
23/1/2017
12:13
With the UKX around this level 1450/60 may be unlikely without some
unexpectedly poor news imv.

essentialinvestor
23/1/2017
10:55
23rd jan Berenberg hold tp 1850p cut from 1885p
philanderer
23/1/2017
09:14
GSK, Will Gap fill back to Dec 5 Low around 1450/60.
garycook
20/1/2017
11:32
Market has allowed me to add some more stock at lower prices tks!
ny boy
20/1/2017
09:50
20th jan Jefferies buy tp 1780p up from 1750p
philanderer
Chat Pages: Latest  547  546  545  544  543  542  541  540  539  538  537  536  Older